<jats:title>ABSTRACT</jats:title><jats:p><jats:named-content content-type="genus-species">Plasmodium vivax</jats:named-content>is the world's most widely distributed malaria parasite and a potential cause of morbidity and mortality for approximately 2.85 billion people living mainly in Southeast Asia and Latin America. Despite this dramatic burden, very few vaccines have been assessed in humans. The clinically relevant vectors modified vaccinia virus Ankara (MVA) and the chimpanzee adenovirus ChAd63 are promising delivery systems for malaria vaccines due to their safety profiles and proven ability to induce protective immune responses against<jats:named-content content-type="genus-species">Plasmodium falciparum</jats:named-content>thrombospondin-related anonymous protein (TRAP) in clinical trials. Here, we describe the development of new recombinant ChAd63 and MVA vectors expressing<jats:named-content content-type="genus-species">P. vivax</jats:named-content>TRAP (PvTRAP) and show their ability to induce high antibody titers and T cell responses in mice. In addition, we report a novel way of assessing the efficacy of new candidate vaccines against<jats:named-content content-type="genus-species">P. vivax</jats:named-content>using a fully infectious transgenic<jats:named-content content-type="genus-species">Plasmodium berghei</jats:named-content>parasite expressing<jats:named-content content-type="genus-species">P. vivax</jats:named-content>TRAP to allow studies of vaccine efficacy and protective mechanisms in rodents. Using this model, we found that both CD8<jats:sup>+</jats:sup>T cells and antibodies mediated protection against malaria using virus-vectored vaccines. Our data indicate that ChAd63 and MVA expressing PvTRAP are good preerythrocytic-stage vaccine candidates with potential for future clinical application.</jats:p>